Cell therapy company Bone Therapeutics (Euronext Brussels:BOTHE) (Euronext Paris:BOTHE) announced on Tuesday that it has completed its acquisition of a majority shareholding in Medsenic, a privately held, clinical stage biotech company.
Incorporated in France, Medsenic specialises in the development of optimised formulations of arsenic Trioxide (ATO) and their applications in serious inflammatory/autoimmune conditions and other potential new indications in related fields.
Medsenic's shareholders have contributed 51% of the total outstanding share capital of Medsenic, valued at EUR40.8m, at a subscription price per share of EUR0.45, which values Bone Therapeutics at EUR10m. In exchange for the in-kind contribution of 51% of Medsenic's shares, 90,668,594 shares were issued by Bone Therapeutics to Medsenic shareholders.
The transaction was approved during an extraordinary meeting of Bone Therapeutics' shareholders held on Monday.
Shareholders also approved Bone Therapeutics' name change to BioSenic. This will be implemented in the next few days and the company's ticker symbol on Euronext will change from 'BOTHE' to 'BIOS'. Its new corporate website will be www.biosenic.com.
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP
RemeGen's Telitacicept receives US FDA Fast Track Designation
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis